HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the use of reduced intensity conditioning regimen in patients with
high risk hemoglobinopathy Sickle Cell and B-Thalassemia Major in combination with standard
immunosuppressive medications, followed by a routine stem cell transplant in order to assess
whether or not it is as effective as myeloablative high dose chemotherapy and transplant.